anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine composition for treating exogenous fever. The traditional Chinese medicine composition is prepared from 3-12 parts of herba menthae, 10-35 parts of pubescent holly roots, 5-10 parts of radix bupleuri, 5-25 parts of herba artemisiae annuae, 10-30 parts of radix ranunculi ternati, 5-12 parts of bombyx batryticatus, 5-12 parts of periostracum cicadae, 10-35 parts of herba houttuyniae, 5-12 parts of radix peucedani and 2.5-10 parts of radix glycyrrhizae. All components of the traditional Chinese medicine composition are mixed according to the monarch and minister principles of traditional Chinese medicine theory, the herba menthae and the pubescent holly roots which have the efficacy of dispelling wind and clearing away heat and toxic materials serve as monarch drugs, wherein the herba menthae is capable of dispelling wind, clearing away heat, relieving the sore throat and eliminating heat, and the pubescent holly roots are capable of clearing away heat and toxic materials, so that the two types of drugs serve as the monarch drugs. The radix bupleuri is capable of dispelling heat, and the radix bupleuri, the radix ranunculi ternati and the herba houttuyniae which are capable of clearing away toxic materials and dispelling heat jointly serve as ministerial drugs. The periostracum cicadae and the herba houttuyniae form &#39;shengjiang powder&#39;, the periostracum cicadae is capable of dispelling wind and heat, the herba houttuyniae is capable of dispelling wind, removing stasis and relieving pain, the herba artemisiae annuae is capable of bringing down deficiency heat and relieving summer heat, the radix peucedani is capable of depressing qi, eliminating phlegm and dispersing wind-heat, and the four types of drugs are combined to serve as the ministerial drugs. The radix glycyrrhizae is capable of clearing away heat and toxic materials and is mild in drug property, so that the radix glycyrrhizae serves as the conductant drug. All medicinal materials in the formula cooperate with one another to jointly achieve the effects of dispelling wind and heat, clearing away heat and toxic materials, relieving symptoms and bringing down heat, when the traditional Chinese medicine composition is used for treating exogenous wind-heat type fever, the curative effect is definite, and the effective rate is high.
An improved method of inducing whole-body hyperthermia and enhanced anti-tumor immune response through inoculation of a fever virus with nil mortality and subsequent injection of irradiated tumor cells derived from the patient. This therapy will safely reduce the tumor burden by 90-99.9% by physical means (fever), before raising intererferon levels to over 250 times baseline. The Activated Lymphokine Killer cells produced by these high interferon levels are capable of killing any cell expressing viral or tumor antigens, even those which had previously escaped immune surveillance. As a fin final step in the process, a specific class of Cytotoxic T Lymphocytes programmed to destroy the patient&#39;s own cancer cells will be produced by repeated inoculation of dendritic cells harvested from the patient. Through a combination of three methods never previously integrated into a single regimen, it is logical to state that this therapy has a high probability of completely eradicating cancer cells from the patient. In addition, this therapy provides for life-long immunity to the reoccurrence of the disease.
FIELD: medicine; neurosurgery; surgical treatment of ischemic disease of brain. SUBSTANCE: first surgeon must provide surgical access to operation field, and must mobilize carotid artery of vertebral artery. Thereupon, o prevent thrombogenesis, patient&#39;s vascular bed must be subjected to heparinizing treatment according to generally accepted procedures for vascular surgery by intravenously administering 5 ths.units heparin. It is generally assumed that heparin starts acting, on average, upon passage of 5 min. after injection. Next, upon passage of 3 min., also intravenously, 1 mg delargin diluted in 2-3 ml of physiological solution is administered. Upon expiration of 2 min, i. e. time required for neuropeptide to start acting, patient&#39;s blood flow in artery being operated is interrupted by applying artery forceps or special spring-urged clamps onto artery&#39;s proximal and distal segments. Finally, surgeon must proceed to required reconstructive surgical operation for eliminating main pathogenic factor causing ischemic disease of brain. EFFECT: enhanced treatment efficiency.
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC). A portable system for mounting a solar panel includes a modular base defining a set of interconnecting components that assemble via a set of intra-assembly features into a portable base for a solar panel. The modular base includes lower and upper relief to provide passive ventilation to the interior of the modular base and recesses to accommodate a user&#39;s appendages during assembly, and ballast volumes to retain a non-rigid ballast to weight the module base holding it in place. The modular base includes adjustable panel retention structures to constrain solar panels of a range of dimensions and configured to carry moisture away from the solar panel. The modular base includes a set of latches and corresponding latch receivers to fix adjacent modular bases together at a fixed distance less than the width of a human hand to form an array.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic for the scalp and the hair, having excellent effects for reducing a greasy state and smell of the scalp and the hair, and excellent stability with the lapse of time in a preparation shape.  &lt;P&gt;SOLUTION: The cosmetic for the scalp and the hair contains (A) an essence of eucalyptus, (B) a polyhydric alcohol and (C) one or more kinds selected from (c1) an antiseborrheic agent and (c2) an antioxidant. Preferably, (D) a polar oil component is contained therein. Especially, the antiseborrheic agent is preferably selected from an extract of cashew, pyridoxine hydrochloride, an extract of Cuachalalate, clove oil, eugenols, flutamide, 3-deoxyadenosine, cyproteron acetate, 11α-hydroxyprogesterone, chlormadinone acetate, ethynylestradiol, spironolactone and episterone. The antioxidant is preferably selected from an essence of Engelhardtia chrysolepis, an essence of soybean, an essence of black tea, an essence of green tea and an essence of rose fruit.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing an extraction component composition of a salmon ovary membrane administrable by percutaneous administration to develop the effect comparable or superior to oral administration.  &lt;P&gt;SOLUTION: The ovary membrane of salmon is treated with the first proteinase to extract the first component. The first component is treated with the second proteinase different from the first proteinase to obtain the second component having a molecular weight lower than the first component. Preferably, the method is further provided with the treatment of the second component with an ultrahigh-pressure emulsifier under a pressure of 980-2,940 MPa to obtain particles having an average particle diameter of 200-1,400 nm. The second proteinase is selected from the group comprising a proteinase composed of a mixture of a plurality of endoproteases and exoproteases produced by an actinomycete, papain, and protease K, especially preferably a mixture of a plurality of endoproteases and exoproteases produced by an actinomycete.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To stably store and transport an aromatic diamine useful as hair dye for a long period while preventing degradation due to coloring, etc., by pressure-filling an aromatic diamine aqueous solution by means of inert gas into a closed container previously filled with inert gas and then by storing and transporting it in a closed state. SOLUTION: An aqueous solution of an aromatic diamine (pref. 2,5- diaminoalkylbenzene such as 2,5-diaminotoluene) is pressure-filled with inert gas into a closed container previously filled with inert gas (pref. nitrogen gas) and then by storing and transporting it in a closed state pref. at &lt;=35 deg.C. The aqueous solution can contain a reducing substance (pref. ascorbic acid). It is pref. that the oxygen content in the closed container is &lt;=10 ppm and the closed container has a filling port and takeoff in a state separated from each other so as for the contents to be discharged without introducing air from outside atmosphere.
PURPOSE:To obtain the subject composition effective in remarkably suppressing the decomposition of disodium adenosine triphosphate and capable of giving a stable drug preparation having increased commercial value, by using a low- melting oil and fat substance as a stabilizer and compounding the substance to disodium adenosine triphosphate. CONSTITUTION:The objective stabilized pharmaceutical composition can be produced by adding a low-melting oil and fat substance in the form of solid or liquid to disodium adenosine triphosphate (abbreviated as ATP-2Na) of formula useful for the amelioration, remedy, etc., of cerebrovascular disorder, cardiac insufficiency and asthenopia and compression-molding the mixture. The melting point of the low-melting oil and fat substance is usually 20-90 deg.C. The substance is preferably an aliphatic ester of a polyhydric alcohol (e.g, polyethylene glycol 6000), higher alcohol ether, alkylene oxide (co)polymer, etc., and its amount is &gt;=0.1pts.wt. per 1pt.wt. of ATP-2Na. The composition is effective in prolonging the quality assurance period, mitigating the preservation condition and increasing the commercial value.
PURPOSE:To provide a granular fungicide handy to carry, storable for a long period without losing the activity, suitable for the preparatory washing, and composed of granular acidic polysaccharide capsules containing an aqueous solution of benzalkonium chloride as a core and made water-insoluble by benzalkonium chloride. CONSTITUTION:Granules composed of an acidic polysaccharide insolubilized by benzalkonium chloride as the outer layer and an aqueous solution of benzalkonium chloride as the core (preferably the diameter of the granule is 0.2-5mm.) are prepared by contacting 1pt. of a 0.1-40% fluid aqueous solution of a water- soluble acidic polysaccharide with 0.1-5pts. of an aqueous solution containing &gt;=0.01% of benzalkonium chloride under agitation of one or both of the components. The fungicidal effect of benzalkonium chloride can be exhibited by collapsing the capsule with pressure in use. The acidic polysacchride is e.g. carrageenan, agar, sodium alginate, gum arabic, CMC-Na, carboxymethylguar sodium salt, etc.
Thus, the invention provides a new method for generating a multi purpose cost/benefit analysis based on the generation of a multi dimensional database. Starting from this database, different models for various medical scenarios can be created. 
     More precisely, the present invention is related to a method and a database for optimizing design, delivery and implementation of innovative products in healthcare. More precisely, a current treatment scenario of a patient is being loaded from a memory, a default case or a stored scenario from previous customer interviews or publication. The current treatment scenario is modified by input relating to new options such as application of a new health care product. Effects on the current healthcare provider&#39;s cost, resource utilization and medical outcome record are determined. Viewpoints of single or various stakeholders involved can be activated. Multiple scenarios can easily be created, so stakeholders can investigate sensitivity of their scenario to key uncertainties.
&lt;P&gt;PROBLEM TO BE SOLVED: To deactivate a singlet oxygen in an active oxygen in order to prevent aging of human skin and prevent deterioration of foods.  &lt;P&gt;SOLUTION: The deactivator is obtained by dissolving uric acid in water as a saturated aqueous solution or suspending uric acid in a viscous liquid such as glycerol. The singlet oxygen in active oxygen is deactivated by uniformly applying the deactivator to the human skin to prevent aging of the skin. A food, etc., is stored and packaged by using a packaging material obtained by impregnating a packaging material with an aqueous solution of uric acid and drying the impregnated material. As a result, singlet oxygen is deactivated to prevent deterioration of the food.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention relates to a Chinese medicine preparation which is compounded from halimasch powder cultured through liquid fermentation, astragalus root and angelica and is used for treating cerebral embolism, hypertension and cerebral arteriosclerosis. The preparation is prepared from the components as raw materials by the following weight compounding ratio: 120 to 180 g of halimasch powder, 200 to 280 g of astragalus root and 50 to 70 g of angelica. The present invention has the advantages of reasonable prescription, obvious curative effect and no side effect. Compared with the similar medicine, the present invention has the advantage of low cost. By clinical observation, the present invention is used for treating disease symptoms, such as dizziness, headaches, numbness of the limbs, tinnitus, hemiplegia, etc., which are caused by cerebral embolism, hypertension, cerebral arteriosclerosis, etc. The total effective rate is 94.0 %, and the total effective rate of the medicine for treating vascular dementia is 76 %. The patients&#39; clinical symptoms can be obviously improved, the patients&#39;neurologic impairment integral is reduced, and the patients&#39; daily living capability can be obviously enhanced.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a more effective targeted drug delivery system for biologics, particularly for polynucleotides and oligonucleotides.  &lt;P&gt;SOLUTION: There are provided pharmaceutical compositions and methods for delivery of therapeutic agents. The methods and compositions can achieve site specific delivery of a therapeutic substance, particularly for agents such as oligonucleotides which have presented problems in reaching targeted sites in necessary therapeutic levels. Targeted introduction of ultrasound can be used to promote release of the therapeutic agent. The delivery system includes protein-encapsulated gas-filled microbubbles formed in an N&lt;SB&gt;2&lt;/SB&gt;-depleted or N&lt;SB&gt;2&lt;/SB&gt;-free environment. These microbubbles are smaller and more stable than microbubbles sonicated in the presence of room air.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention comprises 3-isoreserpic acid of the formula &lt;FORM:0823707/IV (b)/1&gt; together with esters thereof wherein the carboxyl group is esterified and the hydroxyl group is free or esterified and also the corresponding salts with acids or bases.  The compounds are prepared by (a) epimerization of reserpic acid or an ester thereof or salt of such acid or ester with a &#34;Lewis acid,&#34; e.g. carboxylic acids, aromatic sulphonic acids, BF3, or hydrohalic acids; or (b) treatment of tetradehydroreserpic acid or ester thereof or salt of such acid or ester with sodium borohydride.  Subsequent hydrolytic or esterification processes may be performed.  Specified esterifying acids are acetic, phenylacetic, benzoic, furane-2-carboxylic acid and particularly 3 : 4 : 5-trimethoxybenzoic acid.  Examples detail the preparation of methyl O-p-toluene-sulphonyl- and O-acetyl-3-isoreserpates, methyl 3-isoreserpate, its nitrate, methyl 3-isoreserpine and its nitrate. Specification 744,290 is referred to.ALSO:3-Isoreserpic acid, its esters and their salts with acids and bases are incorporated into hydrophilic ointments to form sun screen compositions.  Also by conversion to quaternary compounds with reactive esters of higher alcohols, e.g. lauryl alcohol, the compounds can be used as disinfectants, and are active against Staphylococcus aureus. Specification 744,290, [Group IV (b)], is referred to.
FIELD: medicine. SUBSTANCE: innovation deals with triamteren- and hydrochlorthiazide-based preparation. Triamteren is separately reduced with polyvinylpyrrolidone at 1:0.03-1:0.03-0.035 ratio, then reduced active substances are mixed with microcrystalline cellulose and additional supplements such as starch at 18- 22% amount, milk sugar at 32-37% amount and aerosil at 0.5-1.5% amount against total amount of preparation. Technical result of the present innovation is more simplified technology in obtaining the above-mentioned composition at simultaneous manufacturing simple and available tabletted form of medicinal preparation, higher tablet&#39;s strength at its simultaneous quick decomposition in water. EFFECT: improved technology. 1 ex, 1 tbl
PCT No. PCT/JP94/00007 Sec. 371 Date Nov. 10, 1994 Sec. 102(e) Date Nov. 10, 1994 PCT Filed Jan. 6, 1994 PCT Pub. No. WO94/15934 PCT Pub. Date Jul. 21, 1994A quinoline-3-acetic acid derivative of the formula    &lt;IMAGE&gt;  (I)  wherein R1, R2 and R3 are the same or different and each is a hydrogen atom or a halogen atom, R4 is a hydrogen atom, a halogen atom or a substituted or unsubstituted lower alkyl, R5 is an optionally esterified carboxyl and the broken line means an optional presence of a double bond, and a pharmaceutically acceptable salt thereof. The novel compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and are highly safe. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.
PURPOSE:A powdery deodorant excellently effective for body smell such as axillary odor, body odor, etc., containing an inorganic substance selected from alkaline earth metallic silicate and carbonate or silica as a main component and porous hollow and spherical fine particles having specific particle diameters as an active ingredient. CONSTITUTION:A powder deodorant containing an inorganic substance (e.g. magnesium silicate, calcium silicate or calcium carbonate) selected from alkaline earth metallic silicate and carbonate or silica as a main component and approximately completely spherical porous hollow and spherical fine particles having 0.3-10mum particle diameter as an active ingredient. Since the inorganic substance has large specific surface area and is basic, it neutralizes lower fatty acids such as butyric acid, isovaleric acid, caproic acid, etc., and deodorizes body smell. Since the silica has very large specific surface area of 100-800m&lt;2&gt;/g, it adsorbs ammonia, amine, etc., and effectively deodorizes body smell. The deodorant has good fluidity and good feeling in use.
In some embodiments, a management system is configured to dynamically generate and/or adjust a step-by-step care regimen. The care regimen, or step-by-step plan, is broken down by the system into specific actions presented to a patient at specific times with tailored guidance on how to achieve the best effect of each step. The system can be configured to build tailored care plans that span contemplation phases, preparation phases, recovery phases, and long term care phases. In further embodiments, over the treatment life cycle, the system facilitates patient care compliance, planning and education, among other options. In other embodiments, the system is configured to dynamically capture and develop implicit relationship information on a patient&#39;s care journey, and augment care options for respective patients responsive to identifying implicit connections developed within the context of the patient&#39;s care journey (e.g., specified by patient provider, procedure, physician, comorbidities, etc.).
&lt;PICT:0467924/III/1&gt; &lt;PICT:0467924/III/2&gt; &lt;PICT:0467924/III/3&gt; &lt;PICT:0467924/III/4&gt; Skin creams, pastes, powders, &amp;c. in non-liquid form which are consumed in stages are enclosed in receptacles provided with radioactivating devices so arranged that in consequence of relative movement between the device and the material to be activated, only that portion of the latter which is next to be used is effectively treated.  The radioactive material 4, Fig. 1, may be enclosed in a capsule 5 resting on the surface of the mass 2 to be treated or it may be immersed just within the surface of the material.  In the arrangement shown in Fig. 3, the radioactive material is enclosed in cavities 22 in a plate 23 connected by a chain 24 to a cap 25 so that the plate 22 may be withdrawn into the lid 3 when the mass 2 is to be used.  A product such as a stick of shaving soap may be treated as shown in &lt;PICT:0467924/III/5&gt; &lt;PICT:0467924/III/6&gt; Fig. 5 in which a capsule 18 containing the radioactive material is pressed by means of a spring 19 against the end of the stick next to be consumed.  Substances to be extruded from a tube 16, Fig. 6, are treated by material mounted in a tubular extension 15 which is secured on the outlet of the tube.  The Specification as open to inspection under Sect. 91 comprises also matter relating to the activation of liquids in which an activating source is placed within or beneath a bottle, e.g. a spraying bottle or the bottle shown in Fig. 4 (Cancelled) in which a lower compartment 9 in which the source 4 is enclosed is connected to an upper compartment by a neck closed by a cock 11. A spray producer may be provided with radioactivating means located in the passage from the air supply to the container or in the passage for the issuing spray.  In an arrangement shown in Fig. 13 (Cancelled), a semi-liquid (or liquid) product is enclosed in a container 1 within an outer container 38 on the lid of which is mounted a screw-threaded conduit 36 carrying a plunger 37 which on being forced down by rotating the conduit causes the extrusion of the contents.  A device for application to the exterior of a cylindrical receptacle consists of a ring or helix on which radioactive material is applied.  This subject-matter does not appear in the Specification as accepted.